Carnegie acted as adviser to OXiGENE Inc. in the publicly traded at Nasdaq (US), and in the secondary offering of USD 10 million to Swedish investors. OXiGENE Inc. was unofficial listing on the SBI list, Stockholm. OXiGENE Inc. is a pharmaceutical development within cancer treatment.July, 1995.
Healthcare
SBI-listing and new share issues in OXIGENE Inc. (US/SE) — Amount not disclosed.
July 1995